Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chronic Myeloproliferative Disorders|Colorectal Cancer|Head and Neck Cancer|Leukemia|Lung Cancer|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: DRUG: doxorubicin hydrochloride|DRUG: motexafin gadolinium
Sponsor: University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)